戻る Agenda
Solution Circle: QPPV Perspective on Brexit - Is Your Pharmacovigilance System Compliant?
Session Chair(s)
APCER Life Sciences
United States
Brexit has brought about changes in pharmacovigilance requirements for products authorized in the United Kingdom. Get a perspective from a qualified person for pharmacovigilance in the European Union (EU-QPPV) and the United Kingdom (UK-QPPV) on the guidance about new regulations, their impact on established pharmacovigilance systems and processes, impact of Brexit on pharma industry, major challenges related to MAH, QPPV and PV system in North Ireland and lessons learned by the Pharmaceuticals.
Speaker(s)
Frank Laschewski, DrMed
APCER Life Sciences Limited, United Kingdom
QPPV
Sameen Wasif
APCER Life Sciences, United Kingdom
UK QPPV
Kanwalpreet Kaur, MD
APCER Life Sciences, Limited, United Kingdom
QPPV & Head of Strategic Development Group